Dexmedetomidine is a new alpha2-agonist that received FDA approval in 1999 for use as a
short-term (less than 24 h) sedativeanalgesic in the intensive care unit. The use of alpha2 …

Background Gastrointestinal motility disturbances in critically ill patients are frequent in the
ICU setting, causing considerable discomfort and are associated with increased rates of …

Postoperative hyperalgesia (POH) is a condition characterized by signs and symptoms of
pain despite the provision of conventional analgesia. In most cases, anesthesiologists are …

JUSTIFICATIVA E OBJETIVOS: A dexmedetomidina é um novo agonista alfa2-adrenérgico
que apresenta relação de seletividade entre os receptores alfa2: alfa1 de 1600: 1, com …

Background: The supraclavicular brachial plexus blocks are one of the most commonly
performed upper limb brachial plexus blocks. These blocks not only provides very good …

Results: In Group D, 22 out of 40 (55%) patients did not have any myoclonus during
induction with etomidate, and none of the patients had grade 3 (severe) myoclonus. In …

JUSTIFICATIVA E OBJETIVOS: A dexmedetomidina é um novo agonista alfa2-adrenérgico,
havendo, atualmente, crescente interesse no seu uso em Anestesiologia, por reduzir o …

La dexmedetomidina es un derivado imidazólico muy potente y un agonista alfa-2
adrenérgico altamente selectivo, con propiedades simpaticolíticas, analgésicas, amnésicas …

BACKGROUND: There are always efforts to find better and safer local anaesthetics along
with adjuvants for supraclavicular brachial plexus block. Levobupivacaine, has strongly …

Background: In this study, we evaluated the efficacy of premedication with
dexmedetomidine, pregabalin, and dexmedetomidine-pregabalin combination for …